Number of participants reporting an adverse event · people with eczema
It is very uncertain whether topical active treatment in combination with moisturiser changes number of participants reporting an adverse event compared with topical active treatment alone (very low certainty).
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Topical active treatment in combination with moisturiser may leads to lower number of participants who experienced a flare compared with topical active treatment alone (low certainty).
1 finding from 1 review
Change from baseline in health‐related quality of life · people with eczema
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Eradication of MRSA · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
Active treatment showed no clear difference in eradication of MRSA: number of participants that were MRSA‐negativea compared with observation only (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: CFRSD‐CRISS symptom score · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Change in weight (kg) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Exacerbation frequency · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Proportion of patients (or ears) with complete clearance of ear wax · adults and children with ear wax requiring removal
Ear drops (any active treatment) may leads to higher proportion of patients (or ears) with complete clearance of ear wax compared with no treatment (low certainty).
1 finding from 1 review
Discomfort/pain · adults and children with ear wax requiring removal
Ear drops (any active treatment) may leads to lower adverse effects: discomfort, irritation or pain compared with no treatment (low certainty).
1 finding from 1 review
Proportion of patients (or ears) with complete clearance of ear wax · adults and children with ear wax requiring removal
Ear drops (any active treatment) may leads to higher proportion of patients (or ears) with complete clearance of ear wax compared with ear drops (water or saline) (low certainty).
1 finding from 1 review
Discomfort/pain · adults and children with ear wax requiring removal
Ear drops (any active treatment) may leads to lower adverse effects: discomfort, irritation or pain compared with ear drops (water or saline) (low certainty).
1 finding from 1 review
Intervention not reported
No active treatment (No direct RCT) · people with liver cirrhosis and ascites
It is very uncertain whether the intervention changes no active treatment (No direct RCT) (very low certainty).
1 finding from 1 review
HR 1.66 [0.46, 6.99]
Studies not reported
Very low
Smoking cessation · participants who used tobacco products
It is very uncertain whether interventions delivered by dental professionals changes multi‐session behavioural support versus usual care, brief advice,… compared with control (very low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated global change in eczema symptoms at the end of active treatment (binary outcome) Change in risk for worsened/unchanged eczema Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in primary outcome 1: participant‐ or parent‐rated global change in… (low certainty).
1 finding from 1 review